Figure 4.
MRD-negativity rates during treatment in the intention to treat population (N = 39) and concordance between NGS and NGF methods. (A) This table shows the MRD-negativity rates overall and stratified by cytogenetic risk. HRC is defined as del(17p) and/or t(4;14) and/or t(14;16) and/or t(14;20) and/or gain or amplification of 1q. (B-C) Panel B shows the postinduction MRD concordance between NGS and NGF methods at 10−5 and 10−6 sensitivity, whereas panel C shows the MRD concordance between NGS and NGF methods at 10−5 and 10−6 sensitivity for the best MRD status. Sample size for each of the concordance analyses include patients with results from both NGS and NGF testing at the applicable sensitivity.
